FSD Pharma (TSE:HUGE) has released an update.
FSD Pharma has secured ethics committee approval in Australia for a Phase-1 clinical trial of their groundbreaking drug candidate Lucid-21-302, aimed at treating multiple sclerosis. The compound, which has demonstrated neuroprotective qualities and the potential to prevent myelin sheath damage in preclinical models, marks a significant advancement in FSD Pharma’s neurodegenerative disease portfolio. Additionally, the company has settled debts by issuing shares, further solidifying their financial strategy.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
